Research programme: anti-Ebola therapies - RedHill Biopharma

Drug Profile

Research programme: anti-Ebola therapies - RedHill Biopharma

Alternative Names: Ebola Therapy - RedHill Biopharma

Latest Information Update: 05 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator RedHill Biopharma
  • Developer National Institute of Allergy and Infectious Diseases; RedHill Biopharma
  • Class Antivirals
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Ebola virus infections

Most Recent Events

  • 29 May 2018 RedHill Biopharma has patent protection for experimental Ebola therapy in USA
  • 10 Aug 2017 RedHill Biopharma plans a preclinical study for Ebola virus infections in USA in the fourth quarter of 2017, following approval by the National Institute of Allergy and Infectious Diseases
  • 13 Jul 2016 RedHill Biopharma and National Institute of Allergy and Infectious Diseases enter into a research collaboration for Ebola virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top